<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00534859</url>
  </required_header>
  <id_info>
    <org_study_id>G050017</org_study_id>
    <nct_id>NCT00534859</nct_id>
  </id_info>
  <brief_title>PROTECT I, A Prospective Feasibility Trial Investigating the Use of IMPELLA RECOVER LP 2.5 System in Patients Undergoing High Risk PCI</brief_title>
  <acronym>PROTECT I</acronym>
  <official_title>PROTECT I, A Prospective Feasibility Trial Investigating the Use of the IMPELLA RECOVER LP 2.5 System in Patients Undergoing High Risk PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abiomed Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abiomed Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this feasibility study is to demonstrate that the device is safe and
      potentially efficacious for use in patients undergoing high risk Percutaneous Coronary
      Interventions(PCI).Patients will be enrolled if they meet inclusion &amp; exclusion criteria.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACCE Events at 30 days or discharge, whichever is longer</measure>
    <time_frame>30 days or discharge</time_frame>
    <description>Major Adverse Cardiac and Cerebral (MACCE) events defined as death, new myocardial infarction, target vessel revascularization, urgent coronary artery bypass grafting procedure or cerebral vascular accident during and up to 30 days post-device explant or hospital discharge, whichever is longer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from Hemodynamic compromise during PCI procedure</measure>
    <time_frame>During procedure</time_frame>
    <description>Freedom from Hemodynamic compromise during PCI procedure defined as: Mean Arterial Pressure (MAP) not falling below 60mm Hg for more than 10 minutes during the PCI procedure and additional pressor medication is not required</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other intra-procedural and peri-procedural adverse events</measure>
    <time_frame>During treatment and out to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from Ventricular fibrillation and Tachycardia requiring electrical cardioversion</measure>
    <time_frame>During procedure</time_frame>
    <description>Freedom from the following procedural-related events:
i. Ventricular fibrillation ii. Tachycardia requiring electrical cardioversion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic Success</measure>
    <time_frame>Post-PCI</time_frame>
    <description>Angiographic success defined as residual stenosis &lt;30% after stent implantation or &lt;50% after balloon angioplasty.</description>
  </secondary_outcome>
  <enrollment type="Actual">28</enrollment>
  <condition>Patients Undergoing High Risk PCI.</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High Risk PCI</intervention_name>
    <description>High Risk Percutaneous Coronary Intervention</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent

          -  Non emergent PCI of at least one de novo or restenotic lesion in a native coronary
             vessel or bypass graft

          -  EF &lt;35%

        Exclusion Criteria:

          -  ST Myocardial Infarction

          -  Cardiac Arrest

          -  Cardiogenic Shock

          -  Thrombus Left Ventricle
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William O'Neill, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Not affiliated with Abiomed</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mass General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Womens</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Presbyterian Hospital</name>
      <address>
        <city>New York,</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029-6574</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Heart</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>777030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Netherland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2007</study_first_submitted>
  <study_first_submitted_qc>September 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2007</study_first_posted>
  <last_update_submitted>March 18, 2011</last_update_submitted>
  <last_update_submitted_qc>March 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Carol Pekar/Director of Clinical and Regulatory Affairs</name_title>
    <organization>Abiomed Inc</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

